Vertex Pharmaceuticals Inc
F:VX1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vertex Pharmaceuticals Inc
F:VX1
|
US |
Intrinsic Value
The intrinsic value of 
Vertex Pharmaceuticals Inc (VX1) under the Base Case is 423.21 EUR per share.
Compared with the current market price of 477.85 EUR, the stock appears
Overvalued by 11% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Vertex Pharmaceuticals Does
Vertex Pharmaceuticals is a biotech company that discovers and sells prescription medicines for serious diseases. Its best-known business is cystic fibrosis treatment, where it develops drugs that help correct the underlying protein defect that causes the disease. It also works on medicines for pain, sickle cell disease, beta thalassemia, and other hard-to-treat conditions.
- Headquarters
- United States of America US
- Employees
- 6 400
- IPO date
- Jul 24, 1991
Vertex Pharmaceuticals has a narrow economic moat
Patents covering Vertex’s cystic fibrosis medicines prevent rivals from selling copies, protecting its profits. Competitors must develop and win approval for their own treatments rather than simply reproduce medicines such as Trikafta and Alyftrek.
Read the full moat analysis
Revenue & Expenses Breakdown
Vertex Pharmaceuticals Inc
Earnings Waterfall
Vertex Pharmaceuticals Inc
The intrinsic value for Vertex Pharmaceuticals Inc (VX1) under the Base Case is 423.21 EUR.
Compared with the current market price of 477.85 EUR, the stock appears Overvalued by 11% .
